The week in pharma: action, reaction and insight – week to June 7, 2024

By Barbara Obstoj-Cardwell. Editor

Among important research news last week, Structure Therapeutics released strong Phase IIa trial results for its weight management investigational drug GSBR-1290, and US biotech BridgeBio Pharma announced encouraging Phase II data supporting its candidate infigratinib as a treatment for achondroplasia, the most common form of dwarfism. On the regulatory front, hallucinogenic medicines developer Lykos Therapeutics suffered a major setback last week, when a US Food and Drug Administration (FDA) advisory panel voted against approving its midomafetamine for the treatment of post traumatic distress disorder. There was good news for Geron Corp, whose myelodysplastic syndrome drug imetelstat, now trade named Rytelo, was approved by the FDA.

Structure’s oral GLP-1 delivers compelling obesity efficacy